IDEAYA Biosciences

77 articles with IDEAYA Biosciences

• IDEAYA to Participate in Upcoming May 2021 Investor Relations Event

  5/6/2021

  IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the following upcoming investor relations event.

• IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021

  4/19/2021

  IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the agenda for its inaugural Synthetic Lethality Investor Day.

• IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma

  4/16/2021

  IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced clinical data from the ongoing Phase 1/2 trial evaluating darovasertib monotherapy and binimetinib combination therapy in patients with solid tumors, including Metastatic Uveal Melanoma and Skin Melanoma.

• IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP-Deletion Solid Tumors

  4/15/2021

  IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the Phase 1 clinical trial evaluating IDE397 (ClinicalTrials.gov Identifier: NCT04794699)

• IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib (IDE196) Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma

  4/15/2021

  IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that the company plans to issue a pre-market press release and conduct a webcast on Friday, April 16, 2021, to discuss clinical data from the ongoing Phase 1/2 trial evaluating darovasertib

• IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update

  3/23/2021

  Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion

• IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity

  3/23/2021

  Targeting enrollment of approximately 40 patients in the IDE196 and binimetinib clinical combination Phase 1/2 study in MUM

• IDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG, and Kinase Inhibitor IDE196

  3/11/2021

  IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced publication of abstracts at the 2021 Annual Meeting of the American Association for Cancer Research.

• IDEAYA to Participate in Upcoming March 2021 Investor Relations Events

  3/1/2021

  IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the following upcoming investor relations events.

• IDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day

  2/22/2021

  Topics will include several potential first-in-class Synthetic Lethality programs, including IDE397 (Phase 1), PARG, Pol Theta and Werner Helicase

• IDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors

  2/17/2021

  Dr. Susan L. Kelley was a former clinical development executive in oncology with Bayer and Bristol Myers Squibb, and led the development and regulatory approval of Nexavar®

• IDEAYA Announces IDE397 IND Clearance by U.S. FDA to Initiate Phase 1 and Appointment of Matthew Maurer, M.D., as Vice President, Head of Clinical Oncology and Medical Affairs

  2/8/2021

  Targeting First-Patient-In for IDE397 Phase 1 study in Q1 2021, as a potential best-in-class MAT2A inhibitor for cancer patients harboring MTAP-deletion, which is prevalent in ~15% of all solid tumors

• IDEAYA to Participate in Upcoming February 2021 Investor Relations Events

  2/1/2021

  IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced its participation at the following upcoming investor relations events.

• Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry

  1/19/2021

  Spelman College and IDEAYA Biosciences, Inc. announce partnership for professional development of the next generation of female African American leaders in the biotechnology industry through the Spelman College and IDEAYA Biosciences Health Science and Biotechnology Program.

• 

  Final Highlights from the 2021 J.P. Morgan Healthcare Conference

  1/15/2021

  As the 2021 virtual JP Morgan Healthcare Conference wrapped up, there was still news from companies regarding their deals, pipeline and regulatory updates. Here’s a look.

• IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA

  1/11/2021

  IDE397 is being developed as a potential best-in-class MAT2A inhibitor for MTAP-deletion, which is prevalent in approximately 15% of all solid tumors

• IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor

  1/5/2021

  IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In in the Phase 1 combination study of IDE196 and crizotinib, a cMET inhibitor, in metastatic uveal melanoma.

• IDEAYA to Participate in Upcoming January 2021 Investor Relations Events and Scientific Conferences

  1/4/2021

  IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced its participation at the following upcoming investor relations events and scientific conferences.

• IDEAYA Biosciences Announces Addition to NASDAQ Biotechnology Index

  12/14/2020

  IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced that it has been selected for addition to the NASDAQ Biotechnology Index.

• IDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update

  11/12/2020

  IDE397, a potential best-in-class MAT2A inhibitor for patients with solid tumors having MTAP deletion, targeting an IND-filing in December 2020